Usefulness of Elevations in Serum Choline and Free F2-Isoprostane to Predict 30-Day Cardiovascular Outcomes in Patients With Acute Coronary Syndrome

American Journal of Cardiology

Volumn 104, Issue 5, 2009, Pages 638-643

  LeLeiko, Rebecca M ^a   Vaccari, Christopher S ^a   Sola, Srikanth ^a   Merchant, Nadya ^a   Nagamia, Sameer H ^a   Thoenes, Martin ^b,c   Khan, Bobby V ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHOLINE; ISOPROSTANE DERIVATIVE; TROPONIN I;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; ELECTROCARDIOGRAPHY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; REVASCULARIZATION; TIME;

ACUTE CORONARY SYNDROME; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CHOLINE; F2-ISOPROSTANES; FEMALE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK ASSESSMENT; ROC CURVE;

EID: 68749095208     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2009.04.047     Document Type: Article

References (30)

1. Möckel M., Danne O., Muller R., Vollert J.O., Muller C., Lueders C., Stork T., Frei U., Koenig W., Dietz R., and Jaffe A.S. Development of an optimized multimarker strategy for early risk assessment of patients with acute coronary syndromes. Clin Chim Acta 393 (2008) 103-109
2. Apple F.S., Wu A.H., Mair J., Ravkilde J., Panteghini M., Tate J., Pagani F., Christenson R.H., Möckel M., Danne O., and Jaffe A.S. Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clin Chem 51 (2005) 810-824
3. Danne O., Lueders C., Storm C., Frei U., and Möckel M. Whole blood choline and plasma choline in acute coronary syndromes: prognostic and pathophysiological implications. Clin Chim Acta 383 (2007) 103-109
4. Koenig W., and Khuseyinova N. Biomarkers of atherosclerotic plaque instability and rupture. Arterioscler Thromb Vasc Biol 27 (2007) 15-26
5. Bassuk S.S., Rifai N., and Ridker P.M. High-sensitivity C-reactive protein: clinical importance. Curr Probl Cardiol 29 (2004) 439-493
6. Sabatine M.S., Morrow D.A., Jablonski K.A., Rice M.M., Warnica J.W., Domanski M.J., Hsia J., Gersh B.J., Rifai N., Ridker P.M., Pfeffer M.A., and Braunwald E. Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease. Circulation 115 (2007) 1528-1536
7. Morrow J.D., Frei B., Longmire A.W., Gaziano J.M., Lynch S.M., Shyr Y., Strauss W.E., Oates J.A., and Roberts LJ I.I. Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers: smoking as a cause of oxidative damage. N Engl J Med 332 (1995) 1198-1203
8. Davi G., Ciabattoni G., Consoli A., Mezzetti A., Falco A., Santarone S., Pennese E., Vitacolonna E., Bucciarelli T., Costantini F., Capani F., and Patrono C. In vivo formation of 8-iso-prostaglandin F2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation 99 (1999) 224-229
9. Reilly M.P., Pratico D., Delanty N., DiMinno G., Tremoli E., Rader D., Kapoor S., Rokach J., Lawson J., and FitzGerald G.A. Increased formation of distinct F2 isoprostanes in hypercholesterolemia. Circulation 98 (1998) 2822-2828
10. Wang F.L., and Haubrich D.R. A simple, sensitive, and specific assay for free choline in plasma. Anal Biochem 63 (1975) 195-201
11. Ulus I.H., Ozyurt G., and Korfali E. Decreased serum choline concentrations in humans after surgery, childbirth, and traumatic head injury. Neurochem Res 23 (1998) 727-732
12. Levey A.S., Bosch J.P., Lewis J.B., Greene T., Rogers N., and Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 130 (1999) 461-470
13. Thygesen K., Alpert J.S., White H.D., Jaffe A.S., Apple F.S., Galvani M., Katus H.A., Newby L.K., Ravkilde J., and Chaitman B. Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction: universal definition of myocardial infarction. Circulation 116 (2007) 2634-2653
14. Adams III J.E., Bodor G.S., Davila-Roman V.G., Delmez J.A., Apple F.S., Ladenson J.H., and Jaffe A.S. Cardiac troponin I: a marker with high specificity for cardiac injury. Circulation 88 (1993) 101-106
15. Mair J., Wagner I., Puschendorf B., Mair P., Lechleitner P., Dienstl F., Calzolari C., and Larue C. Cardiac troponin I to diagnose myocardial injury. Lancet 341 (1993) 838-839
16. Malasky B.R., and Alpert J.S. Diagnosis of myocardial injury by biochemical markers: problems and promises. Cardiol Rev 10 (2002) 306-317
17. Bakshi T.K., Choo M.K., Edwards C.C., Scott A.G., Hart H.H., and Armstrong G.P. Causes of elevated troponin I with a normal coronary angiogram. Intern Med J 32 (2002) 520-525
18. Mahajan N., Mehta Y., Rose M., Shani J., and Lichstein E. Elevated troponin level is not synonymous with myocardial infarction. Int J Cardiol 111 (2006) 442-449
19. 2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci USA 87 (1990) 9383-9387
20. Cipollone F., Ciabattoni G., Patrignani P., Pasquale M., Di Gregorio D., Bucciarelli T., Davi G., Cuccurullo F., and Patrono C. Oxidant stress and aspirin-insensitive thromboxane biosynthesis in severe unstable angina. Circulation 102 (2000) 1007-1013
21. 2alpha by human monocytes: discriminate production by reactive oxygen species and prostaglandin endoperoxide synthase-2. J Biol Chem 271 (1996) 8919-8924
22. Pratico D., Iuliano L., Mauriello A., Spagnoli L., Lawson J.A., Rokach J., Maclouf J., Violi F., and FitzGerald G.A. Localization of distinct F2-isoprostanes in human atherosclerotic lesions. J Clin Invest 100 (1997) 2028-2034
23. Pratico D., Rokach J., Lawson J., and FitzGerald G.A. F2-isoprostanes as indices of lipid peroxidation in inflammatory diseases. Chem Phys Lipids 128 (2004) 165-171
24. Brühl A., Hafner G., and Loffelholz K. Release of choline in the isolated heart, an indicator of ischemic phospholipid degradation and its protection by ischemic preconditioning: no evidence for a role of phospholipase D. Life Sci 75 (2004) 1609-1620
25. Konstantinova S.V., Tell G.S., Vollset S.E., Nygård O., Bleie Ø., and Ueland P.M. Divergent associations of plasma choline and betaine with components of metabolic syndrome in middle age and elderly men and women. J Nutr 138 (2008) 914-920
26. Danne O., Möckel M., Lueders C., Mugge C., Zschunke G.A., Lufft H., Muller C., and Frei U. Prognostic implications of elevated whole blood choline levels in acute coronary syndromes. Am J Cardiol 91 (2003) 1060-1067
27. Yue B., Pattison E., Roberts W.L., Rockwood A.L., Danne O., Lueders C., and Möckel M. Choline in whole blood and plasma: sample preparation and stability. Clin Chem 54 (2008) 590-593
28. Miles R.R., Roberts R.F., Putnam A.R., and Roberts W.L. Comparison of serum and heparinized plasma samples for measurement of chemistry analytes. Clin Chem 50 (2004) 1704-1706
29. Sabatine M.S., Morrow D.A., de Lemos J.A., Gibson C.M., Murphy S.A., Rifai N., McCabe C., Antman E.M., Cannon C.P., and Braunwald E. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation 105 (2002) 1760-1763
30. Morrow D.A., Sabatine M.S., Brennan M.L., de Lemos J.A., Murphy S.A., Ruff C.T., Rifai N., Cannon C.P., and Hazen S.L. Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in tactics-TIMI 18. Eur Heart J 29 (2008) 1096-1102